CytoDyn Inc. (OTCQB: CYDY) is set to profit from helping the HIV positive with its lead product candidate, PRO 140. The company is close to submitting a rolling Biologics License Application (BLA) for PRO 140 as a combination therapy with highly active antiretroviral therapy (HAART). The biologic has already been designated a “fast track” product […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.